Serum paraoxonase (PON1) and high density lipoprotein (HDL) are tightly
associated and can protect low density lipoprotein (LDL) from oxidative
modifications by hydrolysis of lipid peroxides and therefore could retard the onset of
atherosclerosis. The aim of the present work is to study PON1 activity and restriction
fragment length polymorphism (Gln
192
–Arg polymorphism) in 30 Egyptian patients
with angiography proven CHD and 30 control subjects. PON1 192 polymorphisms
were analyzed from the genomic DNA of 30 patients and 30 healthy controls by
PCR. Plasma PON1 activities were measured by the hydrolysis of paraoxon using
spectrophotometer at 405 nm. Other parameters were determined using standard
biochemical tests. Distribution or frequency of PON-1 polymorphism among
patients is not statistically significant compared to the PON-1 activity which was
significantly lower in subjects with CHD than control subjects.